Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study

NCT00482248 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00482248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00482248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2003
Completion date
June 30, 2006
Enrollment
132 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma